#United States #New York #Pomerantz Law #Aquestive Therapeutics #AQST

Pomerantz Law Firm Brings Attention to Investors Affected by Aquestive Therapeutics

The Pomerantz Law Firm has initiated a class action lawsuit against Aquestive Therapeutics, Inc. (NASDAQ: AQST), making it imperative for impacted investors to be aware of the situation and upcoming deadlines. The firm urges individuals who sustained losses from their investments in Aquestive to reach out, as they may have a claim against the company for alleged securities fraud.

Class Action Details

Investors are invited to contact Danielle Peyton at Pomerantz either by phone or through email for assistance. To expedite legal proceedings, it is advised that investors include their contact details and the number of shares acquired. The primary objective of this class action is to highlight the potentially unlawful practices by the company and its executives.

Key Timelines

For those who believe they purchased Aquestive securities during the applicable class period, they have until May 4, 2026, to petition the court for appointment as Lead Plaintiff. Documentation relating to the case is accessible via the Pomerantz Law Firm's official website.

Allegations Against Aquestive

The class action stems from accusations that Aquestive and some of its officers were engaged in fraudulent activities. The lawsuit took a significant turn on January 9, 2026, when the company disclosed that the U.S. Food and Drug Administration (FDA) had identified deficiencies in the New Drug Application for Anaphylm (Dibutepinephrine), a sublingual film. This information indicated that discussions regarding its labeling were on hold due to ongoing review processes by the FDA. Consequently, the approval timeline for Anaphylm has been significantly delayed, affecting investor confidence.

As a reaction, on the day of the announcement, Aquestive's stock price plummeted by 37.04%, falling $2.30 to close at $3.91 per share, demonstrating a sharp decline in investor sentiment following the FDA's report.

About Pomerantz Law Firm

Founded over 85 years ago by Abraham L. Pomerantz, the Pomerantz Law Firm is regarded as one of the leading firms in the realm of corporate, securities, and antitrust class litigation. The firm is notable for its relentless pursuit of justice on behalf of victims of corporate misconduct and fraud. Their extensive experience has led to multiple significant recoveries for class members.

With offices spread across major cities including New York, Chicago, Los Angeles, as well as international locations in London, Paris, and Tel Aviv, Pomerantz continues to champion for the rights of investors globally.

Next Steps for Investors

Individuals affected by the downturn in Aquestive's stock prices should not rush to fill out forms without considering their options. Engaging with experienced legal counsel can help clarify the path forward. To find further information regarding participation in this class action, reach out directly to the Pomerantz Law Firm. For detailed inquiries, mention your previous investments, contact information, and the dates the shares were acquired.

Stay informed and proactive as the situation with Aquestive Therapeutics develops, as any delays can have extended implications for investors looking to recover losses amidst the challenges faced by the pharmaceutical company.